Summary: New large-scale genetic research clarifies biological mechanisms linking Cannabis Use Disorder (CUD) and psychosis. A meta-analysis of genome-wide association studies identified more than 500 genetic loci associated with psychosis, including 122 novel associations, and reveals distinct molecular pathways that appear to drive the causal effect from heavy cannabis use to psychotic outcomes.
The study shows that the causal relationship between cannabis use and psychosis is mediated by specific biological systems — notably neurodevelopmental processes, neuronal signaling, and neurotransmitter pathways such as the glutamate system — offering a clearer basis for identifying people at greatest risk and for developing targeted interventions.
Key Research Findings
- Bidirectional association: Genetic analyses support a two-way causal relationship between psychosis and cannabis use, but the effect is substantially stronger from CUD to psychosis than the reverse.
- Three distinct genetic mechanisms: For the first time, researchers separated causal variants linking CUD to psychosis into three clusters. These groups implicate genes involved in neurodevelopment, neuronal signaling, and other biological processes that may explain how cannabis exposure triggers psychotic symptoms in susceptible individuals.
- Importance of the glutamate system: Genetic score analyses highlight genes regulating glutamate as potential markers of heightened vulnerability to cannabis-related psychosis. This is biologically plausible because THC, the main psychoactive component of cannabis, is known to influence glutamatergic signaling.
- Broader definition of psychosis: Instead of focusing solely on schizophrenia, the study combined genome-wide association data for schizophrenia and bipolar I disorder to form a more inclusive “psychosis” group, aligning genetic analysis with epidemiological patterns of cannabis use and psychotic illness.
- Asymmetry in causal routes: Only one coherent group of genetic variants was found to mediate the pathway from psychosis to CUD, consistent with clinical experience that pre-existing psychosis leads to heavy cannabis use with less biological variation than the reverse pathway.
Source: King’s College London
Overview of the study
Researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London performed a comprehensive meta-analysis of genome-wide association studies (GWAS) combining cases of schizophrenia and bipolar I disorder to create a larger, clinically relevant psychosis group. Using updated genetic datasets, the team interrogated molecular pathways shared between CUD and psychosis and mapped the genetic architecture underlying their causal relationships.
Their genome-wide analysis uncovered over 500 loci associated with psychosis, including 122 not reported previously. Pathway-level tests showed more nominal overlap between biological processes linked to psychosis and those associated with CUD than expected by chance, reinforcing the view of a substantive genetic and biological connection between the two conditions.
Professor Marta Di Forti, senior author of the study and Professor of Drug Use, Genetics and Psychosis at King’s IoPPN, emphasised the public-health relevance: better genetic understanding can help target prevention efforts and tailor treatments for people who develop psychosis after heavy cannabis exposure. She noted that the stronger causal effect from CUD to psychosis supports prioritising strategies to identify individuals at elevated risk before problematic use occurs.
Dr Isabelle Austin-Zimmerman, the study’s first author, highlighted that the findings indicate multiple biological routes linking cannabis use and psychosis rather than a single mechanism. Distinguishing the genetic fingerprint of psychosis with cannabis exposure from psychosis without such exposure could lead to more personalised clinical approaches.
Key Questions Answered:
A: The genetics indicate both directions are valid, but the causal impact from heavy cannabis use to psychosis is considerably stronger. The analysis identifies three distinct genetic “routes” that help explain how intensive cannabis exposure can precipitate psychotic episodes in susceptible people.
A: THC affects glutamatergic signaling, and the study’s genetic scoring found that glutamate-related genes are linked to increased risk of cannabis-associated psychosis. This suggests glutamate biology could be a useful biomarker for vulnerability.
A: Potentially yes. Demonstrating distinct biological signatures for psychosis with cannabis exposure supports developing tailored interventions and prediction models, moving away from a one-size-fits-all approach to psychiatric care.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full for accuracy.
- Additional explanatory context was provided by the editorial team.
About this genetics and CUD research news
Author: Patrick O’Brien
Source: King’s College London
Contact: Patrick O’Brien – King’s College London
Image: Image credited to Neuroscience News
Original Research: Findings published in Biological Psychiatry: Global Open Science